$4.2 Billion is the total value of Rock Springs Capital Management LP's 123 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HUM | Buy | HUMANA INC | $210,151,100 | +1.5% | 470,000 | +10.2% | 5.00% | +1.2% |
| IMCR | Buy | IMMUNOCORE HLDGS PLCads | $181,583,464 | +22.4% | 3,028,410 | +0.9% | 4.32% | +22.0% |
| PODD | Buy | INSULET CORP | $161,182,060 | -5.9% | 559,000 | +4.1% | 3.84% | -6.1% |
| AGL | Buy | AGILON HEALTH INC | $143,618,550 | -23.3% | 8,282,500 | +5.1% | 3.42% | -23.5% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $138,197,670 | +51.1% | 2,186,672 | +7.6% | 3.29% | +50.7% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $120,656,850 | -1.5% | 1,279,500 | +5.7% | 2.87% | -1.7% |
| EXAS | Buy | EXACT SCIENCES CORP | $88,594,650 | +38.8% | 943,500 | +0.2% | 2.11% | +38.4% |
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $76,072,249 | +24.4% | 2,686,167 | +0.9% | 1.81% | +24.1% |
| AKRO | Buy | AKERO THERAPEUTICS INC | $72,404,704 | +30.1% | 1,550,754 | +6.6% | 1.72% | +29.7% |
| ACHC | Buy | ACADIA HEALTHCARE COMPANY IN | $72,313,120 | +16.3% | 908,000 | +5.5% | 1.72% | +15.9% |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $63,856,329 | +19.2% | 1,384,269 | +3.6% | 1.52% | +18.8% |
| ABCM | Buy | ABCAM PLCads | $58,850,350 | +95.0% | 2,405,000 | +7.2% | 1.40% | +94.4% |
| MIRM | Buy | MIRUM PHARMACEUTICALS INC | $47,102,363 | +9.2% | 1,820,733 | +1.4% | 1.12% | +8.9% |
| PCRX | Buy | PACIRA BIOSCIENCES INC | $41,472,450 | -1.6% | 1,035,000 | +0.2% | 0.99% | -1.8% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $40,525,106 | +2.3% | 1,121,647 | +5.3% | 0.96% | +2.0% |
| PHR | Buy | PHREESIA INC | $40,468,050 | -3.8% | 1,305,000 | +0.2% | 0.96% | -4.0% |
| ACCD | Buy | ACCOLADE INC | $37,985,400 | +3.8% | 2,820,000 | +10.8% | 0.90% | +3.6% |
| KYMR | Buy | KYMERA THERAPEUTICS INC | $34,198,797 | -6.0% | 1,487,551 | +21.1% | 0.81% | -6.2% |
| ZLAB | Buy | ZAI LAB LTDadr | $33,897,790 | -3.8% | 1,222,423 | +15.4% | 0.81% | -4.2% |
| Buy | AMYLYX PHARMACEUTICALS INC | $33,317,367 | -21.8% | 1,544,616 | +6.3% | 0.79% | -22.0% | |
| OLK | Buy | OLINK HLDG ABsponsored ads | $31,012,500 | -16.6% | 1,654,000 | +0.2% | 0.74% | -16.8% |
| NVRO | Buy | NEVRO CORP | $30,793,788 | -21.0% | 1,211,400 | +12.4% | 0.73% | -21.2% |
| IMTX | Buy | IMMATICS N.V | $29,267,102 | +68.7% | 2,536,144 | +0.9% | 0.70% | +68.1% |
| TVTX | Buy | TRAVERE THERAPEUTICS INC | $23,465,779 | -18.3% | 1,527,720 | +19.7% | 0.56% | -18.5% |
| BRKS | Buy | AZENTA INC | $21,934,932 | +14.0% | 469,900 | +9.0% | 0.52% | +13.7% |
| INZY | Buy | INOZYME PHARMA INC | $19,094,428 | +3.7% | 3,428,084 | +6.6% | 0.45% | +3.2% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $17,580,239 | -9.7% | 2,497,193 | +7.0% | 0.42% | -9.9% |
| Buy | DISC MEDICINE INC | $16,137,979 | +143.0% | 363,468 | +16.0% | 0.38% | +143.0% | |
| Buy | WARBY PARKER INC | $15,489,250 | +12.5% | 1,325,000 | +1.9% | 0.37% | +12.5% | |
| BSX | New | BOSTON SCIENTIFIC CORP | $14,469,075 | – | 267,500 | +100.0% | 0.34% | – |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $14,305,397 | -5.7% | 421,615 | +0.0% | 0.34% | -6.1% |
| MRUS | New | MERUS N V | $12,599,721 | – | 478,531 | +100.0% | 0.30% | – |
| EDAP | Buy | EDAP TMS S Asponsored adr | $10,937,686 | -4.1% | 1,186,300 | +15.2% | 0.26% | -4.4% |
| MREO | Buy | MEREO BIOPHARMA GROUP PLCspon ads | $9,295,956 | +110.6% | 7,042,391 | +12.8% | 0.22% | +110.5% |
| Buy | ICOSAVAX INC | $8,623,301 | +72.0% | 868,409 | +0.5% | 0.20% | +70.8% | |
| KRYS | New | KRYSTAL BIOTECH INC | $4,097,377 | – | 34,901 | +100.0% | 0.10% | – |
| NVAX | Buy | NOVAVAX INC | $3,987,681 | +7.5% | 536,700 | +0.2% | 0.10% | +6.7% |
| New | LEAP THERAPEUTICS INC | $3,363,238 | – | 1,074,517 | +100.0% | 0.08% | – | |
| New | ACELYRIN INC | $2,965,208 | – | 141,876 | +100.0% | 0.07% | – | |
| BDTX | New | BLACK DIAMOND THERAPEUTICS I | $2,844,327 | – | 563,233 | +100.0% | 0.07% | – |
| IMGN | New | IMMUNOGEN INC | $2,125,139 | – | 112,620 | +100.0% | 0.05% | – |
| EPIX | Buy | ESSA PHARMA INC | $1,790,956 | +14.9% | 663,317 | +26.4% | 0.04% | +16.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.